Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.

gnorimies20.15 shared this article with you from Inoreader Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature. Via pubmed: esophageal cancer Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature. Cancer Biol Ther. 2020 Oct 23;:1-7 Authors: Liu L, Liu Y, Gong L, Zhang M, Wu W Abstract The current evidence regarding immunotherapy plus targeted therapy in esophageal neuroendocrine carcinoma (NEC) is lacking. Camrelizumab is a programmed cell death protein 1 inhibitor. Apatinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. A 50-year-old female was initially diagnosed as primary esophageal NEC. Neoadjuvant chemotherapy and Ivor Lewis esophagectomy were performed (ypT3N0M0, stage Ⅱ). Twenty months after the surgery, an isolated mediastinal lymph node recurrence of NEC was recorded. The specimen revealed a positive expression of vascular endothelial growth factor and programmed cell death ligand 1. The diseased lymph node was slightly enlarged after two cycles of first-line paclitaxel liposome and S-1. Second-line apatinib and S-1 for 2 months also resulted in progressive disease. Subsequently, third-line camrelizumab plus apatinib was continued for 5 months. The patient demonstrated a progression-free sta tus for more than 10 months following the combination therapy. Meanwhile, relevant studies of camrelizumab in gastric or esophageal cancer were briefly reviewed. Based on the current evidence, camrelizumab is a promising agent for esophageal cancer. More prospective trials are warranted before a definite recommendation could be drawn. PMID: 33092443 [PubMed - as supplied by publisher] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Barretts Esophagus and Esophageal Adenocarcinoma Biomarkers.

gnorimies20.15 shared this article with you from Inoreader Barretts Esophagus and Esophageal Adenocarcinoma Biomarkers. Via pubmed: esophageal cancer Barretts Esophagus and Esophageal Adenocarcinoma Biomarkers. Cancer Epidemiol Biomarkers Prev. 2020 Oct 22;: Authors: Grady WM, Yu M, Markowitz SD, Chak A Abstract Esophageal adenocarcinoma (EAC) is a major cause of cancer related morbidity and mortality in Western countries. The incidences of EAC and its precursor Barrett's esophagus (BE) have increased substantially in the last four decades. Current care guidelines recommend that endoscopy be used for the early detection and monitoring of patients with BE, however, the efficacy of this approach is unclear. In order to prevent the increasing morbidity and mortality from EAC, there is a need for early detection and surveillance biomarker assays that are accurate, low-cost, and clinically feasible to implement. The last decade has seen remarkable advances in the development of minimally invasive molecular biomarkers, an effort led in large part by the Early Detection Research Network (EDRN). Advances in multi-omics analysis, the development of swallowable cytology collection devices, and emerging technology have led to promising assays that are likely to be implemented into clinical care in the next decade, with the most promising markers to date being methylated VIM and CCNA1. In this review, an updated overview of the molecular pathology of BE and EAC and emerging molecular biomarker assays, as well as the role of EDRN in biomarker discovery and validation, will be discussed. PMID: 33093162 [PubMed - as supplied by publisher] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.